BridgeBio Pharma, Inc. Insider Trading Activity

BridgeBio Pharma President and CFO Thomas Trimarchi reported routine equity activity in company stock.

Rhea-AI Filing Summary

BridgeBio Pharma President and CFO Thomas Trimarchi reported routine equity activity in company stock. On May 18, 2026, he made open-market sales totaling 13,651 shares of common stock at weighted average prices around the mid-$60s per share, under a pre-arranged Rule 10b5-1 sales plan. On May 16, 2026, 22,781 shares were withheld to cover taxes tied to the vesting of 41,193 RSUs, which is not an open-market sale. After these transactions, he directly holds 359,194 shares of BridgeBio common stock.

Insider Trade Summary 10b5-1

Net Seller: 13,651 shares

Net Sell 3 txns

Insider Trimarchi Thomas

Role President and CFO

Sold 13,651 shs ($888K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,456	$64.8151	$678K
Sale	Common Stock	3,195	$65.9507	$211K
Exercise Price or Tax Liability	Common Stock	22,781	$66.13	$1.51M

Holdings After Transaction: Common Stock — 359,194 shares (Direct)

Footnotes (4)

1. F1. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 41,193 shares of Common Stock underlying the Reporting Person's RSUs.
2. F2. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.
3. F3. Represents the weighted average sale price of the shares sold from $64.34 to $65.33 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
4. F4. Represents the weighted average sale price of the shares sold from $65.54 to $66.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Key Figures

Open-market sale 1: 3,195 shares at $65.9507 Open-market sale 2: 10,456 shares at $64.8151 Total shares sold: 13,651 shares +5 more

8 metrics

Open-market sale 1 3,195 shares at $65.9507 Common Stock sale on May 18, 2026

Open-market sale 2 10,456 shares at $64.8151 Common Stock sale on May 18, 2026

Total shares sold 13,651 shares Aggregate open-market sales reported in Form 4

Tax withholding shares 22,781 shares at $66.13 Shares withheld for tax on May 16, 2026

RSUs vested 41,193 shares Common Stock underlying RSUs that vested

Post-transaction holdings 359,194 shares Directly owned BridgeBio common stock after May 18, 2026

Tax-withholding count 22,781 shares TaxWithholdingShares in transaction summary

Net share change -13,651 shares NetBuySellShares in transaction summary

Key Terms

Rule 10b5-1 sales plan, RSUs, tax obligation, weighted average sale price, +2 more

6 terms

Rule 10b5-1 sales plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."

RSUs financial

"vesting of 41,193 shares of Common Stock underlying the Reporting Person's RSUs."

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

tax obligation financial

"withheld to satisfy the Reporting Person's tax obligation in connection with the vesting"

weighted average sale price financial

"Represents the weighted average sale price of the shares sold from $64.34 to $65.33 per share."

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

tax-withholding disposition financial

"transaction_action": "tax-withholding disposition""

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/19/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Trimarchi Thomas

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/16/2026		F		22,781(1)	D	$66.13	372,845	D
Common Stock	05/18/2026		S(2)		10,456	D	$64.8151(3)	362,389	D
Common Stock	05/18/2026		S(2)		3,195	D	$65.9507(4)	359,194	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 41,193 shares of Common Stock underlying the Reporting Person's RSUs.

2. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

3. Represents the weighted average sale price of the shares sold from $64.34 to $65.33 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

4. Represents the weighted average sale price of the shares sold from $65.54 to $66.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Remarks:

	/s/ Laura Woodhead, Attorney-in-Fact	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)